XOMA (NASDAQ:XOMA) Stock Rating Lowered by StockNews.com

XOMA (NASDAQ:XOMA) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a report released on Friday.

Separately, HC Wainwright restated a “buy” rating and set a $123.00 price objective on shares of XOMA in a report on Friday, December 13th.

XOMA Stock Performance

Shares of NASDAQ:XOMA opened at $26.30 on Friday. The firm’s 50 day simple moving average is $29.76 and its 200-day simple moving average is $27.82. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52. XOMA has a one year low of $18.24 and a one year high of $35.00. The firm has a market cap of $309.89 million, a PE ratio of -7.56 and a beta of 0.88.

Insider Activity

In other XOMA news, CEO Owen Hughes sold 21,881 shares of the stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total transaction of $655,335.95. Following the sale, the chief executive officer now owns 34,979 shares of the company’s stock, valued at approximately $1,047,621.05. This trade represents a 38.48 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 7.20% of the company’s stock.

Institutional Investors Weigh In On XOMA

Hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp raised its holdings in XOMA by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock worth $1,484,000 after purchasing an additional 1,968 shares in the last quarter. Rhumbline Advisers grew its position in shares of XOMA by 16.0% in the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock worth $230,000 after buying an additional 1,334 shares during the last quarter. Ellsworth Advisors LLC bought a new position in shares of XOMA during the 3rd quarter worth approximately $516,000. BNP Paribas Financial Markets lifted its position in XOMA by 95.0% during the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 795 shares during the last quarter. Finally, State Street Corp lifted its position in XOMA by 1.2% during the third quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock valued at $3,783,000 after acquiring an additional 1,754 shares during the last quarter. 95.92% of the stock is currently owned by hedge funds and other institutional investors.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.